Impact of sustained virologic response on chronic kidney disease progression in hepatitis C

Table 1 Baseline characteristics for patients undergoing treatment for hepatitis C virus at the West Los Angeles Veterans Administration

	All patients (n = 523)	SVR12 not achieved (n = 38)	SVR12 achieved (n = 485)	P value
Age (mean, yr) (SE)	62.7 (0.3)	60.5 (1.1)	63.0 (0.3)	0.02a
Gender (%)
Male (n = 512)	97.9	94.7	97.9	0.81
Female (n = 11)	2.1	5.3	2.1
Ethnicity (%)
White (n = 278)	53.2	52.6	56.3	0.78
Black or African American (n = 174)	33.3	34.3	33.2
American Indian or Alaska Native (n = 11)	2.1	2.6	2.1
Asian (n = 4)	0.8	2.6	0.6
Native Hawaiian or other pacific islander (n = 5)	1.0	0.0	1.0
Unknown/declined to answer (n = 51)	9.8	7.9	9.9
Cirrhosis (%)
Non-cirrhotic (n = 269)	51.4	47.2	51.7	0.31
Cirrhosis (n = 254)	48.6	52.8	48.3
Treatment experience (%)
Treatment naive (n = 406)	77.6	73.7	77.9	0.54
Treatment experienced (n = 117)	22.4	26.3	22.1
HCV genotype (%)
HCV genotype 1a (n = 278)	53.2	50.7	53.3	0.44
HCV genotype 1b (n = 147)	28.1	22.2	28.6
HCV genotype 2 (n = 48)	9.2	12.6	8.9
HCV genotype 3 (n = 40)	7.6	17.1	6.9
HCV genotype 4 (n = 6)	1.1	0.0	1.2
HCV genotype 6 (n = 1)	0.2	0.0	0.2
Combination (n = 3)	0.6	0.0	0.6
Treatment (%)
Dasabuvir, ombitasvir, paritaprevir and ritonavir (n = 104)	19.9	23.7	19.6	0.68
Ledipasvir and sofosbuvir (n = 200)	38.2	44.7	37.7
Simeprevir (n = 55)	10.5	5.3	10.9
Sofosbuvir + Ribavirin (n = 164)	31.4	26.3	31.8
Obesity (%)
BMI < 30 (n = 284)	54.3	63.5	53.6	0.25
Obese (n = 239)	45.7	36.5	46.4
Hypertension (%)
No hypertension (n = 177)	33.8	47.5	32.8	0.07
Hypertension (n = 346)	68.5	52.5	67.2
Diabetes (%)
No diabetes (n = 358)	31.5	73.5	68.1	0.47
Diabetes (n = 165)	30.9	26.5	31.9
Congestive heart failure (%)
No congestive heart failure (n = 501)	95.8	97.4	95.7	0.2
Congestive heart failure (n = 22)	4.2	2.6	4.3
Coronary artery disease (%)
No coronary artery disease (n = 469)	89.7	94.7	89.3	0.12
Coronary artery disease (n = 53)	10.1	2.6	10.7
Peripheral arterial disease (%)
No peripheral arterial disease (n = 508)	97.1	94.7	97.2	0.99
Peripheral arterial disease (n = 15)	2.9	5.3	2.7
Baseline CKD before treatment (%)
Stage 1 CKD (n = 263)	50.3	60.5	49.5	0.24
Stage 2 CKD (n = 218)	41.7	39.5	41.9
Stage 3 CKD (n = 41)	7.8	0.0	8.5
Stage 4 CKD (n = 1)	0.2	0.0	0.2
Diuretic use (%)
No diuretic use (n = 367)	70.2	71.1	70.1	0.9
Diuretic use (n = 156)	29.8	28.9	29.9

^aSignificant P-value, P < 0.05. CKD: Chronic kidney disease; HCV: Hepatitis C virus; SVR12: Sustained virological response at 12 wk following therapy.